Edgewise Therapeutics Holds Annual Meeting, Stockholder Proposals Approved
Ticker: EWTX · Form: 8-K · Filed: Jun 11, 2024 · CIK: 1710072
| Field | Detail |
|---|---|
| Company | Edgewise Therapeutics, Inc. (EWTX) |
| Form Type | 8-K |
| Filed Date | Jun 11, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: annual-meeting, stockholder-vote
TL;DR
Edgewise Therapeutics' shareholders approved all proposals at the annual meeting on June 6th.
AI Summary
On June 7, 2024, Edgewise Therapeutics, Inc. filed an 8-K report detailing several key events. The company announced the results of its annual meeting of stockholders held on June 6, 2024, where all proposals were approved. Additionally, the filing includes financial statements and exhibits related to these events.
Why It Matters
The approval of stockholder proposals at the annual meeting indicates continued support for the company's management and strategic direction.
Risk Assessment
Risk Level: low — This filing is routine and reports on the outcome of an annual stockholder meeting, with no new material financial or operational information that would significantly alter risk.
Key Players & Entities
- Edgewise Therapeutics, Inc. (company) — Registrant
- June 7, 2024 (date) — Date of Report
- June 6, 2024 (date) — Date of Annual Meeting of Stockholders
FAQ
What was the date of Edgewise Therapeutics' annual meeting of stockholders?
The annual meeting of stockholders was held on June 6, 2024.
Were all proposals presented at the annual meeting approved by stockholders?
Yes, all proposals presented at the annual meeting of stockholders were approved.
What is the exact name of the registrant?
The exact name of the registrant is Edgewise Therapeutics, Inc.
In which state was Edgewise Therapeutics, Inc. incorporated?
Edgewise Therapeutics, Inc. was incorporated in Delaware.
What is the principal executive office address for Edgewise Therapeutics, Inc.?
The address of the principal executive offices is 1715 38th St., Boulder, CO 80301.
Filing Stats: 799 words · 3 min read · ~3 pages · Grade level 11.5 · Accepted 2024-06-10 21:09:56
Key Financial Figures
- $0.0001 — h registered Common Stock, par value $0.0001 per share EWTX The Nasdaq Global Se
Filing Documents
- tm2416817d1_8k.htm (8-K) — 40KB
- tm2416817d1_ex3-1.htm (EX-3.1) — 6KB
- 0001104659-24-070114.txt ( ) — 221KB
- ewtx-20240607.xsd (EX-101.SCH) — 3KB
- ewtx-20240607_lab.xml (EX-101.LAB) — 33KB
- ewtx-20240607_pre.xml (EX-101.PRE) — 22KB
- tm2416817d1_8k_htm.xml (XML) — 4KB
03
Item 5.03. AMENDMENTS TO ARTICLES OF INCORPORATION OR BYLAWS; CHANGE IN FISCAL YEAR. On June 10, 2024, following the vote on proposal 3 at the 2024 Annual Meeting of Stockholders (the "Annual Meeting") of Edgewise Therapeutics, Inc. (the "Company"), the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to reflect Delaware law provisions regarding officer exculpation, which amendment was effective upon filing. Specifically, the Certificate of Amendment amended Section 1 of Article IX in its entirety to read as follows: "Section 1. To the fullest extent permitted by the DGCL as the same exists or as may hereafter be amended from time to time, a director or officer of the Company shall not be personally liable to the Company or its stockholders for monetary damages for breach of fiduciary duty as a director or officer. If the DGCL is amended to authorize corporate action further eliminating or limiting the personal liability of directors or officers, then the liability of a director or officer of the Company shall be eliminated or limited to the fullest extent permitted by the DGCL, as so amended." The Certificate of Amendment to the Company's Amended and Restated Certificate of Incorporation is filed as Exhibit 3.1 hereto.
07
Item 5.07. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS. The Company held its Annual Meeting on June 7, 2023. The matters voted upon at the Annual Meeting and the voting results for each proposal are set forth below. Proposal 1: Election of three Class III Directors Name of Director For Withheld Broker Non-Votes Peter Thompson, M.D. 65,082,540 17,277,217 8,220,319 Kevin Koch, Ph.D. 75,368,471 6,991,286 8,220,319 Jonathan Fox, M.D., Ph.D. 71,894,919 10,464,838 8,220,319 Each director nominee was duly elected to serve until the 2027 annual meeting of stockholders and until their successor is duly elected and qualified, subject to earlier resignation or removal. Proposal 2 : Ratification of the Appointment of Independent Registered Public Accounting Firm For Against Abstain 90,540,979 4,016 35,081 The stockholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. Proposal 3 : Amendment to the Amended and Restated Certificate of Incorporation For Against Abstain Broker Non-Votes 81,420,504 937,804 1,449 8,220,319 The stockholders approved the Certificate of Amendment to the Company's Amended and Restated Certificate of Incorporation to limit the liability of certain officers as permitted by Delaware law.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 3.1 Certificate of Amendment to the Company's Amended and Restated Certificate of Incorporation, dated June 10, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EDGEWISE THERAPEUTICS, INC. By: /s/ Kevin Koch Kevin Koch, Ph.D. President and Chief Executive Officer Date: June 10, 2024